From: Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series
Patient | Hybrid MC (Bediol and FM2), N = 18 | |||
---|---|---|---|---|
Decoction | Oil extract | |||
THC (mg) | CBD (mg) | THC (mg) | CBD (mg) | |
Patient #1 | 6 | 8 | 0.66 | 0.55 |
Patient #2 | Â | Â | Â | Â |
Patient #3 | 24 | 32 | Â | Â |
Patient #4 | 36 | 48 | 3.9 | 3.3 |
Patient #5 | 23.6 | 38 | Â | Â |
Patient #6 | Â | Â | 3.12 | 2.64 |
Patient #7 | 6 | 8 | 0.78 | 0.66 |
Patient #8 | 33 | 50 | Â | Â |
Patient #9 | 26.4 | 40 | Â | Â |
Patient #10 | 39.6 | 60 | Â | Â |
Patient #11 | Â | Â | 4.68 | 3.96 |
Patient #12 | 23.6 | 38 | 1.56 | 1.32 |
Patient #13 | Â | Â | Â | Â |
Patient #14 | Â | Â | Â | Â |
Patient #15 | Â | Â | Â | Â |
Patient #16 | 19.8 | 30 | Â | Â |
Patient #17 | Â | Â | 1.8 | 1.65 |
Patient #18 | 19.8 | 30 | Â | Â |
Median | 23.6 | 38 | 1.8 | 2 |
IQR | 13.2 | 18 | 3.12 | 2.64 |
Mean | 23.4 | 34.7 | 2.4 | 2 |
± SD | 10.7 | 16.1 | 1.6 | 1.3 |